The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.
 
Hongyun Zhao
No Relationships to Disclose
 
Lianke Liu
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Wenfeng Fang
No Relationships to Disclose
 
Haiqing Ma
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Guosheng Feng
No Relationships to Disclose
 
Shaodong Hong
No Relationships to Disclose
 
Shan Zeng
No Relationships to Disclose
 
Bo Xie
No Relationships to Disclose
 
Jun Ren
No Relationships to Disclose
 
Xiaoyan Lin
No Relationships to Disclose
 
Yingjun Zhang
Employment - HEC R&D Center; Sunshine Lake Pharma
Leadership - HEC R&D Center; Sunshine Lake Pharma
 
Ning Xi
Employment - HEC R&D Center; Sunshine Lake Pharma
 
Yingzhi Jiang
Employment - HEC R&D Center
 
Yanjun Wu
Employment - HEC R&D Center; HEC R&D Center; Sunshine Lake Pharma; Sunshine Lake Pharma
 
Ning Kang
Employment - Lianke Liu2, Jian Fang3, Haiqing Ma4, Guosheng Feng5, Shan Zeng6, Bo Xie7, Jun Ren8, Xiaoyan Lin9
 
Su Li
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose